The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | The future of menin inhibitors in AML: early investigations into their use in the frontline setting
Ioannis Mantzaris, MD, Montefiore Medical Center/Albert Einstein College of Medicine, New York City, NY, discusses the future of menin inhibitors in the treatment of acute myeloid leukemia (AML). He highlights early trials investigating these agents in the frontline setting, in combination with 7+3 chemotherapy or venetoclax plus hypomethylating agent (HMA). Dr Mantzaris places emphasis on evaluating the safety of these combinations, adding that they may open up many opportunities for the future. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yeah, I think again, this is the question for the future. Menin inhibitors currently are mainly studied in the relapsed/refractory setting. We saw a couple of attempts to bring them earlier in the treatment paradigm in the upfront setting as well, either in combination with 7+3 in some trials for the fit population or HMA-VEN for the unfit population. These are all great alternatives and we have to see first how to do that in a safe manner to identify you know potential toxicity signals that we might need to be aware of...
Yeah, I think again, this is the question for the future. Menin inhibitors currently are mainly studied in the relapsed/refractory setting. We saw a couple of attempts to bring them earlier in the treatment paradigm in the upfront setting as well, either in combination with 7+3 in some trials for the fit population or HMA-VEN for the unfit population. These are all great alternatives and we have to see first how to do that in a safe manner to identify you know potential toxicity signals that we might need to be aware of. But certainly if that works out, if the combination is safe and if that combination produces high-quality responses, I think we’re gonna face a good problem to have. How do we choose between, you know, let’s say 7+3 venetoclax or 7+3 and a menin inhibitor down there on for the subset of patients that menin inhibition is relevant, obviously, NPM1 or KMT2A or any of the other more rare genetic lesions that could be potentially targeted by menin inhibition. So I think there is a lot for the future. It’s too early to be able to make any prediction or compare any of those approaches. But I think it opens up a lot of opportunity for the future.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
